Live

Mitochondria, potential new therapeutic targets in pancreatic cancer -

What we have done and what we continue to do….

For more than 15 years, the oncogenomic platform of the Molecular Oncology Laboratory (Dir: D. Birnbaum, Institut Paoli Calmettes – CRCM) has made a major contribution to the molecular characterization of genomic alterations associated with various cancers (over 120 publications).

Since 2013, our laboratory has focused on the molecular characterization of genomic alterations in cancers (mainly breast, pancreatic and colorectal cancers and myeloid leukaemias) by next-generation sequencing (NGS) and comparative genomic hybridization (aCGH) to better understand the progression of these diseases, identify alterations associated with the different stages of disease progression (Colette et al, Blood Cancer Journal 2015; Cervera et al., Leukemia 2016; Cervera et al., Blood Cancer J. 2017; Courtier et al., Haematologica 2017; Bertucci et al., Oncotarget 2016; Tyran et al., Cancers 2019) and develop a predictive molecular drug that helps guide treatment decisions (Gonçalvès et al., Oncotarget 2016; Bertucci et al., Nature 2019).